Monday, April 10, 2017

Sorafenib pathways published in Pharmacogenetics and Genomics


The PharmGKB review of the Sorafenib pathways has been published in the journal Pharmacogenetics and GenomicsSorafenib (NEXAVAR®, BAY43-9006) is an oral anti-cancer drug approved for the treatment of metastatic or advanced liver, kidney, and thyroid cancers.  Although many new targeted therapies have been tested over the past decade, sorafenib remains the standard of care for these diseases due to its modest efficacy and acceptable tolerability. In this review, we discuss the pharmacokinetic and pharmacodynamic properties of sorafenib and highlight genetic variations that may contribute to the diverse pharmacological responses to sorafenib. 


Find out more...
View interactive pathways on PharmGKB:
Sorafenib Pharmacokinetics Pathway
Sorafenib Pharmacodynamics Pathway

Read our new publication:
Pharmacogenet Genomics. 2017 Mar 30
Gong Li, Giacomini Marilyn M, Giacomini Craig, Maitland Michael L, Altman Russ B, Klein Teri E

PMID: 28362716


View all pathways on PharmGKB.


No comments: